Literature DB >> 25054293

Chemoprotection in glioblastoma therapy: reality or a dream?

Maciej M Mrugala1, Jennifer Adair, Hans-Peter Kiem.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 25054293      PMCID： PMC6176791          DOI： 10.2217/cns.12.11

Source DB:  PubMed          Journal:  CNS Oncol        ISSN： 2045-0907


× No keyword cloud information.
  14 in total

1.  A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma.

Authors:  Manfred Westphal; Dana C Hilt; Enoch Bortey; Patrick Delavault; Robert Olivares; Peter C Warnke; Ian R Whittle; Juha Jääskeläinen; Zvi Ram
Journal:  Neuro Oncol       Date:  2003-04       Impact factor: 12.300

Review 2.  Microdialysis for assessing intratumoral drug disposition in brain cancers: a tool for rational drug development.

Authors:  Jaishri Blakeley; Jana Portnow
Journal:  Expert Opin Drug Metab Toxicol       Date:  2010-10-23       Impact factor: 4.481

3.  Efficient and stable MGMT-mediated selection of long-term repopulating stem cells in nonhuman primates.

Authors:  Brian C Beard; Grant D Trobridge; Christina Ironside; Jeannine S McCune; Jennifer E Adair; Hans-Peter Kiem
Journal:  J Clin Invest       Date:  2010-06-14       Impact factor: 14.808

4.  Direct reversal of DNA damage by mutant methyltransferase protein protects mice against dose-intensified chemotherapy and leads to in vivo selection of hematopoietic stem cells.

Authors:  S Ragg; M Xu-Welliver; J Bailey; M D'Souza; R Cooper; S Chandra; R Seshadri; A E Pegg; D A Williams
Journal:  Cancer Res       Date:  2000-09-15       Impact factor: 12.701

5.  Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.

Authors:  H S Friedman; J Pluda; J A Quinn; R B Ewesuedo; L Long; A H Friedman; I Cokgor; O M Colvin; M M Haglund; D M Ashley; J N Rich; J Sampson; A E Pegg; R C Moschel; R E McLendon; J M Provenzale; E S Stewart; S Tourt-Uhlig; A M Garcia-Turner; J E Herndon; D D Bigner; M E Dolan
Journal:  J Clin Oncol       Date:  2000-10-15       Impact factor: 44.544

6.  MGMT gene silencing and benefit from temozolomide in glioblastoma.

Authors:  Monika E Hegi; Annie-Claire Diserens; Thierry Gorlia; Marie-France Hamou; Nicolas de Tribolet; Michael Weller; Johan M Kros; Johannes A Hainfellner; Warren Mason; Luigi Mariani; Jacoline E C Bromberg; Peter Hau; René O Mirimanoff; J Gregory Cairncross; Robert C Janzer; Roger Stupp
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

7.  High-dose BCNU with autologous bone marrow rescue for recurrent glioblastoma multiforme.

Authors:  F H Hochberg; L M Parker; T Takvorian; G P Canellos; N T Zervas
Journal:  J Neurosurg       Date:  1981-04       Impact factor: 5.115

Review 8.  Vector design for expression of O6-methylguanine-DNA methyltransferase in hematopoietic cells.

Authors:  Axel Schambach; Christopher Baum
Journal:  DNA Repair (Amst)       Date:  2007-05-07

9.  Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma.

Authors:  Jennifer A Quinn; Sara Xiaoyin Jiang; David A Reardon; Annick Desjardins; James J Vredenburgh; Jeremy N Rich; Sridharan Gururangan; Allan H Friedman; Darell D Bigner; John H Sampson; Roger E McLendon; James E Herndon; Amy Walker; Henry S Friedman
Journal:  J Clin Oncol       Date:  2009-02-09       Impact factor: 44.544

10.  Long-term polyclonal and multilineage engraftment of methylguanine methyltransferase P140K gene-modified dog hematopoietic cells in primary and secondary recipients.

Authors:  Brian C Beard; Reeteka Sud; Kirsten A Keyser; Christina Ironside; Tobias Neff; Sabine Gerull; Grant D Trobridge; Hans-Peter Kiem
Journal:  Blood       Date:  2009-03-31       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.